ライブ

FierceBiotech'Biopharma ecosystem is back to full health,' fueled by M&A: PwC FierceBiotechJazz, AbCellera strike TCE discovery and development deal worth up to $792M per drug Endpoints NewsJazz turns to AbCellera for T cell engagers in up to $4.1B partnership Endpoints NewsSpot Bio launches with $40M to study mRNA therapy for muscular dystrophy Endpoints NewsTriveni Bio raises $65M ahead of upcoming readouts on eczema drugs CellCellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology CellA CRISPR knockout mouse library for functional genomics in influenza research Endpoints NewsMigraine biotech Vedana Therapeutics makes its debut with $46M Series A BioPharma DiveA new Westlake-backed biotech takes aim at migraines eLifeCorrection: The myeloid cell-driven transdifferentiation of endothelial cells into pericytes promotes the restoration of BBB function and brain self-repair after stroke 10x Genomics NewsTXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary - Stock Titan Clinical OMICsCancer Diagnostics: Droplet Digital PCR Testing for HPV+ Cancer in the Clinic

BioPharma Dive 2026年6月17日

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly pop...

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 